CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
| Project Number | pCODR 10045 |
|---|---|
| Brand Name | Avastin |
| Generic Name | Bevacizumab |
| Strength | 25mg/mL |
| Tumour Type | Gynecology |
| Indication | Cervical Cancer |
| Funding Request | In combination with chemotherapy for the treatment of patients with persistent, recurrent, or metastatic carcinoma of the cervix |
| Review Status | Notification to Implement Issued |
| Pre Noc Submission | Yes |
| NOC Date | N/A |
| Manufacturer | Hoffmann-La Roche Limited |
| Sponsor | Hoffmann-La Roche Limited |
| Submission Date | October 27, 2014 |
| Submission Deemed Complete | November 3, 2014 |
| Submission Type | New Indication |
| Prioritization Requested | Requested and Not Granted |
| Stakeholder Input Deadline ‡ | November 10, 2014 |
| Check-point meeting | December 16, 2014 |
| pERC Meeting | February 19, 2015 |
| Initial Recommendation Issued | March 5, 2015 |
| Feedback Deadline ‡ | March 19, 2015 |
| Final Recommendation Issued | March 23, 2015 |
| Notification to Implement Issued | April 8, 2015 |
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
